Aim: This observational study investigates the effectiveness and safety of dabrafenib/trametinib combination in patients with metastatic melanoma. Patients & methods: Seventy-six patients treated with dabrafenib/trametinib (150 mg twice daily/2 mg once daily) were included. Results: Median progression-free survival was 9 months (95% CI: 7-11) and median overall survival was 14 months (11-16); disease control rate was 72%. Nine patients (12%) experienced a complete response. Of these, seven presented one metastatic site, none had lung or CNS metastasis, and none had elevated baseline lactate dehydrogenase (LDH) levels. Overall, subgroup analysis for patients with adverse prognostic features led to similar results. No new safety signals were reported. Conclusion: Dabrafenib/trametinib combination can be effective and well-tolerated also in a heterogeneous 'real life' population comprising patients with adverse prognostic features.

Dabrafenib-trametinib combination in 'field-practice': An Italian experience / Depenni, R.; De Rosa, F.; Greco, S.; Ridolfi, L.; Pellacani, G.; Ponti, G.; Cascinu, S.; Guidoboni, M.. - In: FUTURE ONCOLOGY. - ISSN 1479-6694. - 14:20(2018), pp. 2045-2052. [10.2217/fon-2017-0714]

Dabrafenib-trametinib combination in 'field-practice': An Italian experience

Depenni R.;De Rosa F.;Pellacani G.;Ponti G.;Cascinu S.;
2018

Abstract

Aim: This observational study investigates the effectiveness and safety of dabrafenib/trametinib combination in patients with metastatic melanoma. Patients & methods: Seventy-six patients treated with dabrafenib/trametinib (150 mg twice daily/2 mg once daily) were included. Results: Median progression-free survival was 9 months (95% CI: 7-11) and median overall survival was 14 months (11-16); disease control rate was 72%. Nine patients (12%) experienced a complete response. Of these, seven presented one metastatic site, none had lung or CNS metastasis, and none had elevated baseline lactate dehydrogenase (LDH) levels. Overall, subgroup analysis for patients with adverse prognostic features led to similar results. No new safety signals were reported. Conclusion: Dabrafenib/trametinib combination can be effective and well-tolerated also in a heterogeneous 'real life' population comprising patients with adverse prognostic features.
7-ago-2018
14
20
2045
2052
Dabrafenib-trametinib combination in 'field-practice': An Italian experience / Depenni, R.; De Rosa, F.; Greco, S.; Ridolfi, L.; Pellacani, G.; Ponti, G.; Cascinu, S.; Guidoboni, M.. - In: FUTURE ONCOLOGY. - ISSN 1479-6694. - 14:20(2018), pp. 2045-2052. [10.2217/fon-2017-0714]
Depenni, R.; De Rosa, F.; Greco, S.; Ridolfi, L.; Pellacani, G.; Ponti, G.; Cascinu, S.; Guidoboni, M.
File in questo prodotto:
File Dimensione Formato  
depenni2018.pdf

non disponibili

Tipologia: Versione dell'editore (versione pubblicata)
Dimensione 1.66 MB
Formato Adobe PDF
1.66 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11380/1183176
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 1
social impact